Acquisition by Mahal Jeetinder Singh of 900 shares of Jasper Therapeutics at 7.1 subject to Rule 16b-3
| JSPR Stock | USD 20.47 2.00 8.90% |
Slightly above 71% of Jasper Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Jasper Therapeutics suggests that many traders are alarmed. Jasper Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Jasper Therapeutics. Many technical investors use Jasper Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Jasper |
Filed transaction by Jasper Therapeutics Officer: Chief Operating Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Jasper Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Jasper Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Jasper Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Jasper Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Jasper Therapeutics Fundamental Analysis
We analyze Jasper Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Jasper Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Jasper Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jasper Therapeutics stock to make a market-neutral strategy. Peer analysis of Jasper Therapeutics could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics with similar companies.
Peers
Jasper Therapeutics Related Equities
| INZY | Inozyme Pharma | 1.68 | ||||
| ORIC | Oric Pharmaceuticals | 1.07 | ||||
| ELDN | Eledon Pharmaceuticals | 0.45 | ||||
| HOOK | Hookipa Pharma | 0.47 | ||||
| IKNA | Ikena Oncology | 0.60 | ||||
| INBX | Inhibrx | 0.88 | ||||
| EWTX | Edgewise Therapeutics | 1.88 | ||||
| ABOS | Acumen Pharmaceuticals | 1.93 | ||||
| EPIX | ESSA Pharma | 2.38 | ||||
| EQ | Equillium | 4.11 | ||||
| XLO | Xilio Development | 5.83 | ||||
| DSGN | Design Therapeutics | 8.79 | ||||
| LYRA | Lyra Therapeutics | 10.00 |
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.